COO Matthew Miller to depart June 16, 2023; duties assumed by President Virnich

Oncology Institute, Inc.

Dr. Matthew Miller terminated as COO effective June 16, 2023; severance includes 3 months base salary and healthcare.
Option exercise period extended to May 18, 2024, contingent on signing a general release of claims.
No replacement will be hired; President Dr. Daniel Virnich will absorb COO responsibilities.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Matthew Miller

Chief Operating Officer

TOI · Oncology Institute, Inc.

Effective: 2023-06-16
Filed: May 22, 2023, 7:59 PM ET

In connection with the Company’s termination of its Chief Operating Officer, Matthew Miller, M.D., effective June 16, 2023, on May 18, 2023, the Company notified Dr. Miller of his termination from his position as the Chief Operating Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew Miller was terminated as Chief Operating Officer at Oncology Institute, Inc..

Action: terminated
Role: Chief Operating Officer

Exact text from the filing

In connection with the Company’s termination of its Chief Operating Officer, Matthew Miller, M.D., effective June 16, 2023, on May 18, 2023, the Company notified Dr. Miller of his termination from his position as the Chief Operating Officer of the Company.

View on SEC.gov

Oncology Institute, Inc. filing history →

Source: SEC EDGAR

accession 0001799191-23-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.